Core Viewpoint - Sionna Therapeutics is focused on transforming the treatment of cystic fibrosis (CF) by developing innovative medicines that normalize the function of the CFTR protein [2]. Company Overview - Sionna Therapeutics is a clinical-stage biopharmaceutical company dedicated to revolutionizing CF treatment through novel medicines aimed at restoring CFTR function [2]. - The company aims to deliver differentiated therapies that stabilize the nucleotide binding domain 1 (NBD1) of the CFTR protein, which is believed to be crucial for improving clinical outcomes and quality of life for CF patients [2]. - Sionna is advancing a pipeline of small molecules designed to correct defects caused by the F508del genetic mutation in NBD1 and is also developing complementary CFTR modulators to enhance CFTR function [2]. Investor Engagement - Sionna will participate in investor events, including the Cantor Global Healthcare Conference on September 3, 2025, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025 [4]. - Live webcasts of these presentations will be available on the company's Investor Relations website, with replays accessible after the events [1][3].

Core Insights - Skye Bioscience, Inc. will host a virtual KOL event on September 4, 2025, to discuss the upcoming topline results from the Phase 2a CBeyond™ trial of nimacimab, a first-in-class peripheral CB1 antibody for obesity [1][2] - The event aims to provide clarity on what constitutes success in the proof-of-concept study, focusing on safety, tolerability, and new preclinical insights related to nimacimab [2][7] Company Overview - Skye Bioscience is a clinical-stage biotechnology company focused on developing new therapeutic pathways for obesity and metabolic health disorders [1][8] - The company is conducting a Phase 2a clinical trial for nimacimab, which is designed to inhibit peripheral CB1 and is also assessing its combination with a GLP-1R agonist [8] KOL Event Highlights - The event will feature discussions with leading obesity experts, including Skye's CEO, Punit Dhillon, who will address the significance of safety and tolerability benchmarks in the obesity treatment landscape [2][7] - Key opinion leaders participating include Dr. Kevin Cannon, Dr. Sean Wharton, and Dr. Marcus Goncalves, who bring extensive experience in metabolic health and obesity research [3][4][6] Research Focus - The event will cover the mechanism and potential role of peripheral CB1 inhibition as a differentiated anti-obesity therapeutic pathway [7] - Newly generated preclinical data with nimacimab will be highlighted, contributing to the understanding of its potential advancement into Phase 2b development [2][7]

Group 1 - Apellis Pharmaceuticals will participate in several upcoming investor conferences, including the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, and Baird Global Healthcare Conference [1] - The dates and times for the conferences are September 3, 2025, at 8:45 a.m. ET, September 4, 2025, at 8:35 a.m. ET, and September 9, 2025, at 10:15 a.m. ET respectively [1] - Live webcasts of the conferences will be available on the company's website, with replays accessible for approximately 30 days post-event [1] Group 2 - Apellis Pharmaceuticals is a global biopharmaceutical company focused on complement science, developing therapies for challenging diseases [2] - The company has introduced the first new class of complement medicine in 15 years, with two C3-targeting medicines approved for four serious diseases [2] - Notable breakthroughs include the first therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients aged 12 and older with C3G or primary IC-MPGN, both severe kidney diseases [2]

Core Insights - The Lovesac Company has appointed Alan Boehme to its Board of Directors, effective August 27, 2025, enhancing its leadership with expertise in digital transformation and technology-enabled growth [1][2]. Company Overview - The Lovesac Company, based in Stamford, Connecticut, is known for its innovative furniture products, particularly the Sactionals, which are marketed as "The World's Most Adaptable Couch" [1][4]. - The company focuses on a "Designed for Life" approach, creating high-quality, modular furniture that is built to last and evolve with customer needs [4]. - Lovesac's product range includes Sactionals, Sactionals Reclining seats, premium foam beanbag chairs (Sacs), the PillowSac™ Chair, StealthTech home theater systems, and EverCouch™ [4]. Leadership and Expertise - Alan Boehme brings over 30 years of experience in consumer goods, retail, and manufacturing, having held significant roles such as CIO and CTO at major brands like H&M Group, Procter & Gamble, and The Coca-Cola Company [2][3]. - His current role as Founder & President of Technology Transformation Group Inc. involves advising companies on technology strategy and operational efficiency, further enhancing his value to Lovesac [3]. - Boehme's expertise includes AI, cybersecurity, and retail technology, aligning with Lovesac's innovative model and long-term growth objectives [2][3]. Awards and Recognition - Lovesac has received accolades such as Repreve's 8th Annual Champions of Sustainability Award and Edison Awards' 38th Annual Best New Product Awards for Sustainable Consumer Products, highlighting its commitment to responsible production and innovation [4]. Sales and Marketing Strategy - The company primarily markets and sells its products online through its website, supported by physical retail locations including branded showrooms and partnerships with third-party retailers [4].

REHOVOT, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that the Company's CEO, Gil Efron will participate in a fireside chat and 1x1 investor meeting at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8-10, 2025. Details are as follows: H.C. Wainwright 27th Ann ...

BROOKFIELD, Conn., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Photronics, Inc. (NASDAQ:PLAB), a worldwide leader in photomask technologies and solutions, today reported financial results for its third quarter of fiscal year 2025 ended August 3, 2025. Commenting on the third-quarter performance, Chairman and CEO George Macricostas said, "Photronics delivered very good results in our fiscal third quarter with revenue, profitability and EPS ahead of expectations. Looking ahead, we remain focused on operational efficien ...

Core Insights - ECARX has achieved Automotive SPICE (ASPICE) v4.0 Capability Level 3 (CL3) certification, the highest rating under the ASPICE standard, enhancing its portfolio of certifications necessary for collaboration with leading automakers [1] - The company has established a scalable, compliant software-development backbone through various certifications, including ASPICE v3.1 CL2, CMMI CL3, and ASPICE v3.1 CL3, which strengthens its competitive positioning in the global market [2] - ECARX is committed to developing products in compliance with ISO26262 and ISO21434 standards for functional safety and cybersecurity, further enhancing its competitive edge [2] Company Overview - ECARX is a global automotive technology provider that delivers turnkey solutions for next-generation smart vehicles, including system on a chip (SoC), central computing platforms, and software [4] - Founded in 2017 and listed on Nasdaq in 2022, ECARX has over 1,600 employees across 13 major locations worldwide, including China, the UK, the USA, Singapore, Malaysia, Sweden, and Germany [5] - The company collaborates with notable automakers such as Volkswagen Group, FAW Group, and Dongfeng Peugeot-Citroën, with its products present in over 9.3 million vehicles globally [5] Leadership Perspective - Ziyu Shen, Chairman and CEO of ECARX, emphasized that achieving ASPICE v4.0 CL3 certification reflects the company's focus on R&D capability, quality control, and process maturity, supporting large-scale global mandates like the project with Volkswagen Group [3]

Sales of $115.5 million, Breakeven Net Loss per diluted share Extends Credit Facility to August 2030 CANTON, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Destination XL Group, Inc. (NASDAQ: DXLG), the leading integrated-commerce specialty retailer of Big + Tall men’s clothing and shoes, today reported operating results for the second quarter of fiscal 2025. Second Quarter Financial Highlights Total sales for the second quarter were $115.5 million, down 7.5% from $124.8 million in the second quarter of fiscal 2 ...

Core Insights - Seres Therapeutics, Inc. is a clinical-stage company focused on live biotherapeutics aimed at improving patient outcomes in medically vulnerable populations [2] - The company will present an overview at the H.C. Wainwright Global Investment Conference on September 8, 2025 [1] Company Overview - Seres Therapeutics is known for developing VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024 [2] - The company is currently developing SER-155, which has received Breakthrough Therapy designation for reducing bloodstream infections in adults undergoing allo-HSCT and Fast Track designation for reducing infection risk and graft-versus-host disease in the same patient group [2] - SER-155 has shown a significant reduction in bloodstream infections and related complications compared to placebo in a Phase 1b clinical study [2] Pipeline and Future Plans - The company’s pipeline includes SER-155 and other cultivated live biotherapeutic candidates targeting various disease-relevant pathways [2] - In addition to allo-HSCT, SER-155 and other candidates will be evaluated in other medically vulnerable populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, and patients in intensive care and long-term acute care facilities [2]

BEDFORD, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in September 2025. Upcoming Investor Conferences Morgan Stanley 23rd Annual Global Healthcare Conference:Fireside Chat Date/Time: Monday, September 8, 2025Fireside Chat Time: 2:35 – 3:10 PM ETPresenter: Pravin U. Dugel, MD, Executive Chai ...